U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07311226) titled 'A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants' on Dec. 16.
Brief Summary: This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3033 in Chinese healthy participants. The entire trial cycle includes a 4-week screening period, 1-day treatment period and 12-week follow-up period.
Study Start Date: Dec. 23
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: Placebo
Participants in placebo group will receive placebo SC/IV.
DRUG: IBI3033
Pa...